文献类型：期刊文献

英文题名：Inhibition of LPA-LPAR1 and VEGF-VEGFR2 Signaling in IPF Treatment

作者：Luo, Ya-Li[1];Li, Yan[1];Zhou, Wen[1];Wang, Si-Yu[1];Liu, Yong-Qi[1,2]

第一作者：骆亚莉

通信作者：Liu, YQ[1]

机构：[1]Gansu Univ Chinese Med, Gansu Univ Key Lab Mol Med & Chinese Med Prevent &, Lanzhou 730000, Peoples R China;[2]Gansu Univ Key Lab Mol Med & Chinese Med Prevent &, Gansu Univ Chinese Med, Sch Basic Med, Lanzhou, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Key Lab Mol Med & Chinese Med Prevent &, Gansu Univ Chinese Med, Sch Basic Med, Lanzhou, Peoples R China.|[10735]甘肃中医药大学;

年份：2023

卷号：17

起止页码：2679

外文期刊名：DRUG DESIGN DEVELOPMENT AND THERAPY

收录：;Scopus(收录号：2-s2.0-85170169456);WOS:【SCI-EXPANDED(收录号:WOS:001088233700001)】；

基金：This work was supported by grants from National Nature Foundation (82160846) , provincial Natural Science Foundation (20JR10RA321) , Gansu Provincial Higher Education Innovation Fund Project (2021A-085) .

语种：英文

外文关键词：idiopathic pulmonary fibrosis; VEGFR2; LPAR1

摘要：Due to the complex mechanism and limited treatments available for pulmonary fibrosis, the development of targeted drugs or inhibitors based on their molecular mechanisms remains an important strategy for prevention and treatment. In this paper, the downstream signaling pathways mediated by VEGFR and LPAR1 in pulmonary cells and the role of these pathways in pulmonary fibrosis, as well as the current status of drug research on the targets of LPAR1 and VEGFR2, are described. The mechanism by which these two pathways regulate vascular leakage and collagen deposition leading to the development of pulmonary fibrosis are analyzed, and the mutual promotion of the two pathways is discussed. Here we propose the development of drugs that simultaneously target LPAR1 and VEGFR2, and discuss the important considerations in targeting and safety.